YolTech Therapeutics to Present Positive Clinical Data of YOLT-101 for the Treatment of HeFH at the EAS Congress 2025

YolTech Therapeutics, a clinical-stage gene editing company focused on the development of in vivo genome editing therapies, today announced that interim data from an ongoing IIT clinical study of YOLT-101 will be presented in an oral presentation at the European Atherosclerosis Society (EAS) Congress 2025. YOLT-101 is an investigational in vivo base editing therapy designed to be a single-dose treatment to durably reduce blood LDL-C. The presentation will include safety, sustained reduction in serum PCSK9 and reduction in serum LDL-C in patients with HeFH.

Title:
“IN VIVO BASE-EDITING GENE THERAPY VIA GALNAC-MODIFIED LIPID NANOPARTICLES FOR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HeFH)”

Date & Time: May 5, 2025 | 1:30 PM – 2:30 PM
Location: Glasgow, United Kingdom

Session: Science at a Glance (SaaG) – Lipid Lowering Therapies and Advances in Vascular Therapeutics

We look forward to engaging with the global scientific community in Glasgow — and to shaping the future of cardiovascular medicine.

About EAS:
The European Atherosclerosis Society (EAS) Congress is one of the world’s leading scientific meetings in the field of atherosclerosis and lipid metabolism, bringing together renowned clinicians, researchers, and industry leaders to discuss the latest advancements in cardiovascular science and therapy. The EAS platform plays a pivotal role in shaping the future of lipid management and cardiovascular disease prevention.